Associated Papers
Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies.
Brlek P et al.
Cancers, 2025
Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update.
Naik RR et al.
Frontiers in Pharmacology, 2022
How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.
Cao S et al.
Journal of Molecular Modeling, 2021
Landscape of drug-resistance mutations in kinase regulatory hotspots.
Kim P et al.
Briefings in Bioinformatics, 2021
Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
Li X et al.
European Journal of Medicinal Chemistry, 2020
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.
Gozgit JM et al.
Oncotarget, 2018
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Subbiah V et al.
Cancer Discovery, 2018
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2017
Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.
Plaza-Menacho I et al.
Cellular Signalling, 2014
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
Buffa P et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2014
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.
Breccia M et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2014
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L et al.
Molecular and Cellular Endocrinology, 2013
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V et al.
The Journal of Clinical Endocrinology and Metabolism, 2013
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia.
Price KE et al.
Oncotargets and Therapy, 2013
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.
Deshpande A et al.
Leukemia, 2012
Genetic and biochemical alterations in non-small cell lung cancer.
Johnson JL et al.
Biochemistry Research International, 2012
Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
Dixit A et al.
Biophysical Journal, 2009
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
Sala E et al.
International Journal of Biological Macromolecules, 2006
BAY 43-9006 inhibition of oncogenic RET mutants.
Carlomagno F et al.
Journal of the National Cancer Institute, 2006